Adding Mylotarg to Chemo Fails to Boost Survival in NPM1-Mutated AML

(MedPage Today) -- There was bad news and good news in a phase III trial evaluating intensive chemotherapy with or without gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia (AML) patients with newly diagnosed, NPM1-mutated disease. For...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news